{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:29Z","timestamp":1786985429155,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bmcl.2022.128846","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T04:12:32Z","timestamp":1654920752000},"page":"128846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies"],"prefix":"10.1016","volume":"72","author":[{"given":"Chengze","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizheng","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiwei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128846_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrg1748","article-title":"The epigenetic progenitor origin of human cancer","volume":"7","author":"Feinberg","year":"2006","journal-title":"Nat Rev Genet."},{"key":"10.1016\/j.bmcl.2022.128846_b0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.1787609","article-title":"An operational definition of epigenetics","volume":"23","author":"Berger","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.bmcl.2022.128846_b0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2007.02.006","article-title":"Epigenetics: a landscape takes shape","volume":"128","author":"Goldberg","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2022.128846_b0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"issue":"51","key":"10.1016\/j.bmcl.2022.128846_b0025","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.51.5.786","article-title":"acetylation and methylation of histones and their possible role in the regulation of RNA synthesis","volume":"10.1073\/pnas.51.5.786","author":"Allfrey","year":"1964","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128846_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128846_b0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14821","article-title":"Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial","volume":"179","author":"San-Miguel","year":"2017","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bmcl.2022.128846_b0040","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bmcl.2022.128846_b0045","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bmcl.2022.128846_b0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol Oncol."},{"issue":"370","key":"10.1016\/j.bmcl.2022.128846_b0055","first-page":"737","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"10.1042\/BJ20021321","author":"van Gennip","year":"2003","journal-title":"Biochem J."},{"key":"10.1016\/j.bmcl.2022.128846_b0060","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1021\/jm901358y","article-title":"Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.J","volume":"53","author":"Salmi-Smail","year":"2010","journal-title":"Med Chem."},{"key":"10.1016\/j.bmcl.2022.128846_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111691","article-title":"Indole: A privileged scaffold for the design of anti-cancer agents","volume":"183","author":"Wan","year":"2019","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128846_b0070","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/S0960-894X(01)00552-2","article-title":"Design and synthesis of a novel class of histone deacetylase inhibitors","volume":"11","author":"Lavoie","year":"2001","journal-title":"Bioorg Med Chem Lett."},{"key":"10.1016\/j.bmcl.2022.128846_b0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acs.jmedchem.1c01472","article-title":"Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo","volume":"65","author":"Jiang","year":"2022","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128846_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104462","article-title":"Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs)","volume":"106","author":"Linciano","year":"2021","journal-title":"Bioorg Chem."},{"key":"10.1016\/j.bmcl.2022.128846_b0085","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1021\/jm100007m","article-title":"Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824)","volume":"53","author":"Cho","year":"2010","journal-title":"J Med Chem."},{"issue":"7","key":"10.1016\/j.bmcl.2022.128846_b0095","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.bmcl.2012.01.122","article-title":"Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT(2)C agonists","volume":"22","author":"Conway","year":"2012","journal-title":"Bioorg Med Chem Lett."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128846_b0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","article-title":"Macrophages: obligate partners for tumor cell migration, invasion, and metastasis","volume":"124","author":"Condeelis","year":"2006","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bmcl.2022.128846_b0105","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections","volume":"61","author":"Huang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128846_b0120","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:12Z","timestamp":1760773512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22003225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":21,"alternative-id":["S0960894X22003225"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128846","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128846"}}